Target intelligence / Profile preview

Human telomerase reverse transcriptase peptide–major histocompatibility complex class I complex (hTERT peptide–MHC complex)

Target
hTERT peptide–MHC complex
Molecular classification
Peptide–MHC complex, Tumor-associated antigen, Immune complex, Other
01

Overview

The hTERT peptide–MHC complex is a cell-surface protein complex formed when peptides derived from human telomerase reverse transcriptase (hTERT), a protein highly expressed in the majority of human cancers but not in most normal somatic tissues, are processed and loaded onto major histocompatibility complex (MHC) class I molecules within a cell. These complexes are then exported to the cell surface, where they are recognized by the T cell receptor (TCR) on cytotoxic T lymphocytes, providing a mechanism for immune surveillance and enabling targeted immunotherapies. The hTERT peptide–MHC complex serves as a tumor-specific antigen, making it an attractive target in cancer immunotherapy strategies including TCR-engineered T cells, TCR-like antibodies, and peptide vaccines. Recognition is typically HLA allele-restricted (often HLA-A2 or similar), and the immune response can lead to selective lysis of hTERT-positive cancer cells. The antigen is not entirely tumor-specific, as low-level hTERT expression occurs in certain normal stem cells, leading to a potential but limited risk of off-tumor toxicity. Peptide–MHC complexes such as this one represent a class of immunological targets with high specificity and potential utility in diagnostics, patient monitoring, and therapeutic intervention for a wide range of tumors, and advancing the concept of precision immuno-oncology.

Other names
hTERT peptide/HLA complexTelomerase peptide–MHC complexTelomerase reverse transcriptase peptide–MHC complexTumor-associated peptide–MHC complex (for telomerase)
02

Mechanism of action

Recognition by T cell receptor (TCR) on cytotoxic T lymphocytes, leading to immune-mediated cell killing Targeting by TCR-like monoclonal antibodies or cellular therapies engineered to recognize the specific complex, resulting in direct tumor cell lysis Vaccination to elicit endogenous T cell responses to hTERT-derived peptides presented by MHC class I molecules

03

Biological functions

Immune response activation (specifically cytotoxic T lymphocyte activation)Antigen presentationAnti-tumor immunity
04

Disease associations

Cancer (broad spectrum, due to telomerase positivity in tumors)Potentially other diseases related to altered immune surveillance
05

Safety considerations

Potential for autoimmunity/immune attack on normal cells expressing low levels of hTERTMHC-restriction limits patient population based on HLA genotype (personalized therapy issue)Immune escape via downregulation of antigen presentationOff-tumor toxicity if normal stem cells express sufficient hTERT-derived peptides
06

Interacting drugs

TCR-like antibodies

2 more in the full profile.

07

Biomarkers

Surface presentation of specific hTERT peptide–MHC class I complexes (used to identify telomerase-positive tumor cells and monitor efficacy of immunotherapies targeting this complex)

Beyond the preview

Go deeper on Human telomerase reverse transcriptase peptide–major histocompatibility complex class I complex (hTERT peptide–MHC complex).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Human telomerase reverse transcriptase peptide–major histocompatibility complex class I complex (hTERT peptide–MHC complex).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call